Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

North-east man takes part in groundbreaking research into prostate cancer after losing father and grandfather to disease

Post Thumbnail

A north-east man who lost his father and grandfather to prostate cancer has taken part in groundbreaking research into the treatment options available after being diagnosed himself.

Andrew Mackie was able to recognise the symptoms of the disease when he developed them due to his family history.

And when presented with the choices the Kemnay man decided to go for surgery.

While this was an easy decision for him due to his knowledge of the illness he feels other people in his situation need more information about the options on the table.

The 51-year-old explained how this led him to sign up to share his experience with researchers at Aberdeen University.

“I was asked to participate in the study after my localised cancer treatment.

“My dad was diagnosed at the age of 58 and died at 62.

“For most people who are diagnosed there is not a huge amount of information about the options such as waiting, having an operation, having radiotherapy or brachytherapy.

“People who are diagnosed can face a great deal of anxiety and so it’s good that they will be able to have the facts to empower them.

“Another positive outcome from this is that my daughter decided that as a result she wanted to become a nurse and is in her second year at Stirling University.”

The chief investigator into the research was Thomas Lam, a urological surgeon at Aberdeen Royal Infirmary and an honorary senior lecturer at Aberdeen University.

He explained what was unique about the research.

He said: “The problem we’ve had so far is that each option for treatment only focuses on the outcomes they aim for.

“Each has different priorities, and we want patients to be able to decide what the most important outcomes are for them and choose treatment that will meet their needs.

“The research ran for three years and involved 174 patients, mostly from the UK.

“I would like to thank our sponsors Cancer Research Aberdeen and North East Scotland for making this possible.

“They have also agreed to fund more research which will run for two years.”

Already a subscriber? Sign in